Product portfolio planners, Business development, C-level executives, Heads of R&D, Regulatory affairs, Market access, Mergers and Acquisitions managers, Intellectual property, Pricing & reimbursement
This unique training is focusing on highly evolving areas of Value Added Medicines business development. The participants will explore the scientific, regulatory, intellectual property and clinical challenges of innovative generic portfolio design.
Learning & Key takeaways:
• All training materials will be provided in printed and digital form
• All delegates will receive printed and LinkedIn certificates
• Five hours of networking with industry peers
• An in-depth scientific discussion of different mechanisms that could lead to an added value product
• Selecting the right route to drug approval is an essential part of the added value process
• Case studies of Formulation patents – successes and failures
• Recent cases regarding Formulation patents and Swiss “use” patents
• Consequences of market switch from Brand to INN generics
Generapharm
CEO
Dr. Ross has over 35 years experience in the Generics Industry, the last 15 being at corporate level. He has been intimately involved in strategic planning, pipeline management and related activities. His early industrial experience with Teva and Taro were directed primarily to the US markets but later, as President of IPR, a company jointly owned by PAR and Merck Generics, followed by R&D director for Polpharma, his role expanded to include development for the European markets. Technically Malcolm specialized in development, both of formulations and analytical methodologies and holds a number of patents for novel formulations. In 2006 Malcolm moved to Basel and has worked for Novartis in several roles as well as consulting for a wide range of companies on strategic planning and technical matters. He has conducted many training courses throughout Europe and Asia.
Generapharm
CEO
Dr. Ross has over 35 years experience in the Generics Industry, the last 15 being at corporate level. He has been intimately involved in strategic planning, pipeline management and related activities. His early industrial experience with Teva and Taro were directed primarily to the US markets but later, as President of IPR, a company jointly owned by PAR and Merck Generics, followed by R&D director for Polpharma, his role expanded to include development for the European markets. Technically Malcolm specialized in development, both of formulations and analytical methodologies and holds a number of patents for novel formulations. In 2006 Malcolm moved to Basel and has worked for Novartis in several roles as well as consulting for a wide range of companies on strategic planning and technical matters. He has conducted many training courses throughout Europe and Asia.
For the detailed agenda with a full breakdown of the individual sessions fill out this form.
